1ZP2
| |
4EAW
| HCV NS5B in complex with IDX375 | 分子名称: | 1,2-ETHANEDIOL, DI(HYDROXYETHYL)ETHER, N-{(1S)-3-[(5S)-5-tert-butyl-1-(3,3-dimethylbutyl)-4-hydroxy-2-oxo-2,5-dihydro-1H-pyrrol-3-yl]-1-ethoxy-1-oxido-1,4-dihydro-2,4,1-benzodiazaphosphinin-7-yl}methanesulfonamide, ... | 著者 | Dousson, C.B, Paparin, J.-L, Surleraux, D, Augustin, M, Blaesse, M, Hoeppner, S, Krapp, S, Wenzkowski, C. | 登録日 | 2012-03-22 | 公開日 | 2013-03-27 | 最終更新日 | 2024-02-28 | 実験手法 | X-RAY DIFFRACTION (2 Å) | 主引用文献 | HCV NS5B in complex with IDX375 To be Published
|
|
2HZM
| Structure of the Mediator head subcomplex Med18/20 | 分子名称: | PHOSPHATE ION, RNA polymerase II mediator complex subunit 18, RNA polymerase II mediator complex subunit 20 | 著者 | Lariviere, L, Geiger, S, Hoeppner, S, Rother, S, Straesser, K, Cramer, P. | 登録日 | 2006-08-09 | 公開日 | 2006-09-12 | 最終更新日 | 2024-02-21 | 実験手法 | X-RAY DIFFRACTION (2.4 Å) | 主引用文献 | Structure and TBP binding of the Mediator head subcomplex Med8-Med18-Med20. Nat.Struct.Mol.Biol., 13, 2006
|
|
2HZS
| Structure of the Mediator head submodule Med8C/18/20 | 分子名称: | RNA polymerase II mediator complex subunit 18, RNA polymerase II mediator complex subunit 20, RNA polymerase II mediator complex subunit 8 | 著者 | Lariviere, L, Geiger, S, Hoeppner, S, Rother, S, Straesser, K, Cramer, P. | 登録日 | 2006-08-09 | 公開日 | 2006-09-12 | 最終更新日 | 2023-08-30 | 実験手法 | X-RAY DIFFRACTION (2.7 Å) | 主引用文献 | Structure and TBP binding of the Mediator head subcomplex Med8-Med18-Med20. Nat.Struct.Mol.Biol., 13, 2006
|
|
1YKE
| |
1YKH
| |
5M6U
| HUMAN PI3KDELTA IN COMPLEX WITH LASW1579 | 分子名称: | 4-azanyl-6-[[(1~{S})-1-(4-oxidanylidene-3-phenyl-pyrrolo[2,1-f][1,2,4]triazin-2-yl)ethyl]amino]pyrimidine-5-carbonitrile, Phosphatidylinositol 3-kinase regulatory subunit alpha, Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform | 著者 | Segarra, V, Hernandez, B, Lozoya, E, Blaesse, M, Hoeppner, S, Jestel, A. | 登録日 | 2016-10-26 | 公開日 | 2017-02-01 | 最終更新日 | 2024-01-17 | 実験手法 | X-RAY DIFFRACTION (2.85 Å) | 主引用文献 | Discovery of a Potent, Selective, and Orally Available PI3K delta Inhibitor for the Treatment of Inflammatory Diseases. ACS Med Chem Lett, 8, 2017
|
|